China Grants Conditional Approval for Sinopharm COVID-19 Vaccine... '79.3% Prevention Effectiveness'

Ongoing Research on Immune Persistence and Preventive Effects

[Asia Economy Reporter Naju-seok] The Chinese government has conditionally approved the COVID-19 vaccine developed by the Chinese pharmaceutical company Sinopharm. The Chinese government plans to continue research on the vaccine's immune duration and preventive effectiveness.

According to China's Xinhua News Agency on the 31st, the National Medical Products Administration of China has conditionally approved the vaccine developed by Sinopharm. The preventive effectiveness of the Sinopharm vaccine was announced to be 79.3%, with an antibody positivity rate of 99.5%.

[Image source=Yonhap News]

In comparison, mRNA vaccines developed by U.S. pharmaceutical companies Moderna and Pfizer have about 15 percentage points higher preventive rates than the vaccine developed by Sinopharm.

However, the Sinopharm vaccine has advantages such as being able to be stored at room temperature for a long time and having a low production cost. The State Council of China stated that the safety, efficacy, and distribution capacity of the Sinopharm vaccine are guaranteed and that it meets the standards of the World Health Organization (WHO).

This content was produced with the assistance of AI translation services.